Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection

Linton, 2003, Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem, 49, 253, 10.1373/49.2.253 Mikolajczyk, 2001, A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer, Cancer Res, 61, 6958 Mikolajczyk, 2000, Seminal plasma contains “BPSA” a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia, Prostate, 45, 271, 10.1002/1097-0045(20001101)45:3<271::AID-PROS11>3.0.CO;2-T Mikolajczyk, 2000, A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue, Cancer Res, 60, 756 Mikolajczyk, 2000, “BPSA” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia, Urology, 55, 41, 10.1016/S0090-4295(99)00372-6 Peter, 2001, Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry, Cancer Res, 61, 957 Catalona, 2003, Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml, J Urol, 170, 2181, 10.1097/01.ju.0000095460.12999.43 Mikolajczyk, 2004, Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer, Clin Chem, 50, 1017, 10.1373/clinchem.2003.026823 Naya, 2004, Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer, Urology, 63, 492, 10.1016/j.urology.2003.10.044 Naya, 2005, Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer, Urol Oncol, 23, 16, 10.1016/j.urolonc.2004.07.017 Sokoll, 2008, [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study, J Urol, 180, 539, 10.1016/j.juro.2008.04.015 Stephan, 2009, A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases, Prostate, 69, 198, 10.1002/pros.20872 Canto, 2004, Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer, Urology, 63, 905, 10.1016/j.urology.2003.12.037 Stephan, 2009, Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network, Urology, 74, 873, 10.1016/j.urology.2009.02.054 Catalona, 2004, Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen, J Urol, 171, 2239, 10.1097/01.ju.0000127737.94221.3e de Vries, 2005, Additional use of [-2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer, Urology, 65, 926, 10.1016/j.urology.2004.11.030 Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Bartsch, 2008, Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality, BJU Int, 101, 809, 10.1111/j.1464-410X.2008.07502.x Berger, 2005, Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk, Prostate, 64, 240, 10.1002/pros.20210 DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Hugosson, 2004, Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma, Cancer, 100, 1397, 10.1002/cncr.20126 Postma, 2007, Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Section Rotterdam. A comparison of two rounds of screening, Eur Urol, 52, 89, 10.1016/j.eururo.2007.01.030 van der Cruijsen-Koeter, 2006, Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial. ERSPC Rotterdam, Urology, 68, 615, 10.1016/j.urology.2006.03.015